Maze Therapeutics, Inc. MAZE R2K
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -4.7% CAGR over 5 years.
- Trading 49.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MAZE Maze Therapeutics, Inc. R2K | 26.46 | - | $1.46B | - | -38.15% | -38.67% | - | -4.69% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 165.00M | - | - | 0 | 0 | 0 | 0 | 20.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 35.40M | 36.47M | 32.97M | 38.06M | 46.55M |
| Operating Income | -28.01M | 139.56M | - | - | -35.40M | -36.47M | -32.97M | -38.06M | -26.55M |
| EBITDA | - | - | - | - | -32.10M | -35.83M | -32.39M | -37.56M | -22.90M |
| Interest Expense | - | - | - | - | 0 | - | - | - | 866.00K |
| Pretax Income | - | - | - | - | -32.79M | -33.68M | -30.09M | -34.57M | -24.21M |
| Tax Provision | - | - | -279.00K | -275.00K | - | 0 | 0 | 0 | - |
| Net Income | -32.49M | 139.06M | - | - | -32.79M | -33.68M | -30.09M | -34.57M | -24.21M |
| Diluted EPS | -13.91 | 3.22 | - | - | -1.15 | -0.77 | -0.66 | -0.65 | -0.45 |
| R&D Expense | 21.88M | 19.55M | 19.86M | - | 27.58M | 28.11M | 25.19M | - | 34.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.50M | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 142.90M |
| Operating Income | -111.03M | -98.55M | 57.59M | -142.90M |
| EBITDA | -107.21M | -94.46M | 60.88M | -140.50M |
| Interest Expense | - | - | - | - |
| Pretax Income | -114.94M | -100.42M | 53.40M | -131.12M |
| Tax Provision | - | 0 | 1.17M | 0 |
| Net Income | -114.94M | -100.42M | 52.23M | -131.12M |
| Diluted EPS | -3.29 | -2.87 | 0.08 | - |
| R&D Expense | - | - | 83.50M | 108.45M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -4.69% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +164.34% |
| 6 Months: | -27.90% |
| 3 Months: | -41.96% |
| 1 Month: | +3.04% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 149.96M | 71.50M | 240.54M | 397.13M |
| Current Assets | 106.15M | 34.11M | 201.67M | 349.72M |
| Cash & Equivalents | 99.92M | 29.16M | 196.81M | 189.25M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 432.42M | 445.35M | 551.73M | 42.16M |
| Current Liabilities | 20.78M | 16.32M | 20.67M | 22.56M |
| Long Term Debt | - | 20.08M | - | - |
| Total Debt | 32.05M | 49.62M | 26.63M | 23.31M |
| Total Equity | -282.46M | -373.85M | -311.18M | 354.97M |
| Shares Outstanding | 43.78M | 43.78M | 43.78M | 49.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -99.20M | -86.83M | 75.95M | -111.94M |
| Investing Cash Flow | -3.17M | -441.00K | -1.15M | -170.96M |
| Financing Cash Flow | 1.73M | 16.39M | 92.85M | 275.34M |
| Capital Expenditure | -1.97M | -441.00K | -1.15M | -794.00K |
| Free Cash Flow | -101.17M | -87.27M | 74.81M | -112.73M |
| Net Change in Cash | -100.64M | -70.88M | 167.65M | -7.57M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | 34.4% | - |
| Net Margin % | - | - | 31.2% | - |
| ROE % | 40.7% | 26.9% | -16.8% | -36.9% |
| ROCE % | -86.0% | -178.6% | 26.2% | -38.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 8.25% | 4.57M | $120.85M |
| 2 | TRV GP IV, LLC | 8.08% | 4.47M | $118.38M |
| 3 | Arch Venture Management, Llc | 7.44% | 4.12M | $109.02M |
| 4 | Deep Track Capital, Lp | 6.28% | 3.48M | $92.02M |
| 5 | Janus Henderson Group PLC | 5.17% | 2.86M | $75.65M |
| 6 | Paradigm Biocapital Advisors LP | 4.96% | 2.74M | $72.62M |
| 7 | Blackrock Inc. | 4.64% | 2.57M | $68.01M |
| 8 | a16z Capital Management, L.L.C. | 3.08% | 1.70M | $45.04M |
| 9 | Venrock Adviser, LLC | 2.89% | 1.60M | $42.39M |
| 10 | Vanguard Capital Management LLC | 2.59% | 1.44M | $37.99M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MAZE